Genmab A (GMAB) Long-Term Deferred Tax: 2018-2021
- Genmab A's Long-Term Deferred Tax fell 14.83% to $21.02 in Q2 2021 from the same period last year, while for Jun 2021 it was $21.02, marking a year-over-year decrease of 14.83%. This contributed to the annual value of $20.6 million for FY2020, which is 204.19% up from last year.
- Latest data reveals that Genmab A reported Long-Term Deferred Tax of $21.02 as of Q2 2021, which was down 100.00% from $20.6 million recorded in Q4 2020.
- In the past 5 years, Genmab A's Long-Term Deferred Tax registered a high of $42.7 million during Q4 2018, and its lowest value of $21.02 during Q2 2021.
- For the 3-year period, Genmab A's Long-Term Deferred Tax averaged around $13.2 million, with its median value being $6.8 million (2019).
- The largest annual percentage gain for Genmab A's Long-Term Deferred Tax in the last 5 years was 204.19% (2020), contrasted with its biggest fall of 100.00% (2020).
- Over the past 4 years, Genmab A's Long-Term Deferred Tax (Quarterly) stood at $42.7 million in 2018, then crashed by 84.18% to $6.8 million in 2019, then spiked by 204.19% to $20.6 million in 2020, then fell by 14.83% to $21.02 in 2021.
- Its Long-Term Deferred Tax was $21.02 in Q2 2021, compared to $20.6 million in Q4 2020 and $24.68 in Q2 2020.
